Samelis, G F <br/><br/>
The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.  [electronic resource] 

 -  Urology  Jun 2003 
 - 1211-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1527-9995 
<br/><br/><label>Standard No.: </label>10.1016/s0090-4295(03)00019-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Androgen Antagonists--therapeutic use<br/>Antineoplastic Agents, Hormonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Drug Resistance, Neoplasm--physiology<br/>Estramustine--administration & dosage<br/>Feasibility Studies<br/>Humans<br/>Infusions, Intravenous<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Neoplasm Recurrence, Local--blood<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--blood